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Maternal supply of nutrients is critical for the developing fetus during all stages of 
gestation.  The altered lipid metabolism that is often seen in pregnancies complicated by obesity 
and insulin resistance may negatively impact maternal nutrient supply to the fetus.  More women 
are entering pregnancy overweight or obese.  Recently body mass index (BMI) has been found to 
be a positive predictor for decreased maternal plasma phospholipid concentrations of the long-
chain polyunsaturated fatty acids (LCPUFA) docosahexanoic acid (DHA) and arachidonic acid 
(ARA).  These nutrients play important roles in early development and their availability is 
critical to fetal growth and development.  The purpose of the present study was to assess if 
maternal serum fatty acids in the second trimester of pregnancy are associated with BMI.   
Serum samples are frequently stored after blood draws during pregnancy.  The 
availability of these samples provided the opportunity to examine if serum samples collected 
from non-fasting, pregnant women could provide information similar to what has previously 
been reported for BMI and fatty acid status in pregnancy.   
Sera from 265 women from the Foundation for Blood Research (FBR, Maine) were 
analyzed for fatty acid content using gas chromatography (GC).  The BMIs of each participant at 
approximately 13-18 weeks of gestation were provided by FBR.  Participants were grouped by 
BMI category and fatty acid concentrations were compared across BMI categories.   
There were significant differences for weight percent of the LCPUFA eicosapentanoic 
acid (EPA) as well as for the total ω3 LCPUFA.  In this data set BMI was a negative predictor of 
maternal serum concentrations of DHA and EPA.  These results support previous findings for 
fatty acids in plasma phospholipids of pregnant women.  We conclude that increased BMI may 
negatively impact maternal LCPUFA concentrations and stored sera may be used to further 






Lipids have long been recognized as important dietary substances for growth and 
development.  Recently, there has been considerable interest in the role of dietary lipids, 
specifically essential fatty acids, in the earliest phases of life.  The long chain polyunsaturated 
fatty acids (LCPUFA) docosahexaenoic acid (DHA, 22:6ω3) and arachidonic acid (ARA, 
20:4ω6) are important structural components of membrane phospholipids.  The highest 
concentrations of these LCPUFA, especially DHA, are found in the brain.  Exponential fetal 
accumulation begins during the last trimester of pregnancy and continues until the age of two.  
During the prenatal period the fetus depends on the maternal supply of preformed DHA and 
ARA to meet its needs.  These fatty acids are transferred across the placenta by placental fatty 
acid binding proteins (p-FABP).   
Recent findings suggest that insulin resistance may result in altered lipid metabolism and 
thus impact fetal LCPUFA status.  Insulin resistance in pregnancy is often characterized by 
increased maternal body mass index (BMI).  Due to the increase in the number of women 
entering pregnancy as overweight or obese, concern has been raised regarding insulin resistance, 
which can lead to gestational diabetes mellitus (GDM).  These conditions could prove 
detrimental to the developing fetus in part because of their impact on nutrient supply to the fetus.  
The purpose of the present study is to assess if maternal serum fatty acids are associated with 
maternal BMI in the second trimester of pregnancy.     
Justification 
It is well established that the LCPUFAs DHA and ARA are critical nutrients during early 
development.  They play important roles throughout the lifespan, especially in early infant 
growth, brain, and retinal development.  With more women entering pregnancy as overweight or 
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obese, it is imperative that there be research directed at determining the impact of these 
conditions on the developing fetus.  Because overweight and obesity are often accompanied by 
insulin resistance and impaired lipid metabolism there is the possibility that maternal supply of 
DHA and ARA may be impacted.  Inadequate supply of these nutrients may be detrimental to 
fetal growth.  Results from this study may lend support to the growing body of evidence for 
decreased ω3 LCPUFA status in pregnancies complicated by overweight or obesity.   
Objectives 
1. To measure fatty acids in sera collected in the second trimester of pregnancy from 
a large cohort of pregnant women living in Maine.  
2. To investigate whether serum fatty acid concentrations are associated with 
maternal BMI.  
Research Statement 
It is hypothesized that women with higher BMIs will have lower concentrations of serum 
DHA and ARA than women with lower BMIs.  
Limitations 
1. This is a relational study so we cannot infer causality. 
2. The results of the present study will only be applicable to women of similar age, race, 
parity and health status.   
Definitions 
1. Gestation: the period of fetal development in the uterus from conception to delivery.  
2. Body Mass Index (BMI):  weight in kilograms divided by height in meters squared 
(kg/m
2
).  The most widely used weight-height measure of adiposity.   
3. Essential fatty acids (EFA): those fatty acids that cannot be synthesized by humans and 
must be obtained from the diet to prevent development of disease.  In humans the parent 
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EFAs from which all other fatty acids are derived are linoleic acid (LA, C18:2ω6) and 
alpha-linolenic acid (ALA, C18:3ω3).   
4. Docosahexaenoic acid (DHA, C22:6ω3): A 22-carbon polyunsaturated fatty acid that has 
its first double bond at the third carbon from the omega or methyl end.   
5. Arachidonic Acid (ARA, C20:4ω6): A 20-carbon polyunsaturated fatty acid that has its 
first double bond at the sixth carbon from the omega or methyl end.    
6. Diabetes mellitus: A metabolic disorder characterized by inadequate insulin secretion by 
the pancreas or the inability of certain cells to use insulin resulting in abnormally high 
serum glucose levels.  Diabetes mellitus can be classified as type 1 diabetes, type 2 
diabetes, or GDM.  
Assumptions  
1. The sample size is adequate to reflect the relationship between the variables under 
investigation. 
2. The Hewlett Packard 5890 gas chromatograph is a reliable instrument for measuring 
the concentration of fatty acids in serum samples.  








REVIEW OF LITERATURE 
 
Lipids and Fatty Acids 
Lipids have long been recognized as important and essential dietary substances for 
growth and development.  Although these compounds are chemically diverse, they all share a 
common feature, insolubility in water.  These compounds are necessary for a variety of functions 
in organisms including providing a storage form of energy and providing structural support for 
biological membranes. The most commonly used fats and oils for stored forms of energy are 
derivatives of fatty acids.   
Fatty acids are the simplest class of lipid whose basic structure is that of a chain of 
carbon atoms linked together and flanked by hydrogen atoms.  One end of the fatty acid chain is 
designated the acid end and contains a carboxyl group, while the other end is designated the 
omega (ω) end and contains a methyl group.  A large proportion of the fatty acids found in 
nature contain an even number of carbon atoms in an unbranched chain.   
Fatty acids are subdivided based on their chain length, either short (less than six carbons), 
medium (six to ten carbons) or long (12 or more carbons).  Saturated fatty acids are those that 
have single bonds between carbons and have the maximum amount of possible hydrogen atoms 
linked to all the carbon atoms.  Therefore, monounsaturated fatty acids contain one carbon-
carbon double bond (site of unsaturation) and are missing two hydrogen atoms from the carbon 
chain.  Carbon chains with two or more double bonds are thus termed polyunsaturated fatty acids 
(PUFA) and contain two fewer hydrogen atoms per carbon-carbon double bond or site of 
unsaturation.  The physical properties of fatty acids and also of the compounds that contain them 
are determined by the length and degree of unsaturation of the carbon chain. 
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Fatty acids are further classified based on the location of the first carbon-carbon double 
bond.  An omega-3 (ω3 or n-3) fatty acid is one which has its first double bond at the third 
carbon from the methyl group (omega) end while an omega-6 (ω6 or n-6) fatty acid has its first 
double bond at the sixth carbon from the methyl group end.  These compounds are most often 
identified by their chain length, number of double bonds, and ω3 or ω6 family.     
Human cells lack the enzymes necessary to synthesize some long-chain polyunsaturated 
fatty acids (LCPUFA) and, therefore, depend on the diet to obtain the precursor ω3 and ω6 fatty 
acids.  These fatty acids are thus termed essential fatty acids (EFA).  Alpha-linolenic acid 
(C18:3ω3, ALA) is the ω3 EFA and linoleic acid (C18:2ω6, LA) is the ω6 EFA.  Humans can 
desaturate and elongate the parent EFAs to form several important LCPUFAs.   
Synthesis of Long-Chain Polyunsaturated Fatty Acids (LCPUFA) 
The conversion pathway of LA and ALA to LCPUFA as described by Voss (1991) 
involves a series of elongation and desaturation enzymes and includes several intermediate 
compounds (1).  These chain elongation and desaturation systems occur mainly in the cytosol of 
cells, but can also be found in the mitochondria of brain cells (2-6).  One of the products of LA 
conversion is the 20 carbon LCPUFA arachidonic acid (C20:4ω6, ARA) which can be seen in 
Figure 1.  It is formed by adding two carbon atoms of acetate to the carboxyl group of LA and 
removing four hydrogen atoms (7).  ALA is converted to the LCPUFAs eicosapentaenoic acid 






Figure 1. A schematic of the structure of arachidonic acid.  Upper numbers refer 
to the numbering system from the methyl carbon and lower numbers refer to the number 






Figure 2. A schematic of the structure of docosahexaenoic acid.    
A schematic of the conversion pathway of fatty acids can be seen in Figure 3.  It is 
important to note that the synthesis pathways of ARA and DHA share enzymes which compete 
for substrates.  Also of importance is the fact that synthesis of ω3 and ω6 fatty acids is not 
interconvertible, meaning an LCPUFA of the ω3 series cannot be synthesized from an LCPUFA 
of the ω6 series and vice versa.  Humans obtain ARA and DHA either from synthesis from their 
parent EFAs or from the consumption of animal tissues, with fatty fish being the richest source 
of DHA.  Because humans have a low capacity for de novo lipogenesis and are unable to 
synthesize the EFA, the dietary fatty acid supply is critical for the incorporation of fatty acids 





















Figure 3. A schematic of the conversion pathway of LA and ALA to the LCPUFA 
C20:4ω6, C20:5ωn and C22:6ω3.  
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Importance of ω3 and ω6 Fatty Acids 
The ω3 and ω6 class of fatty acids are important components of storage lipids, cell 
membrane phospholipids, intracellular cholesterol esters and plasma lipids (8).  Animal studies 
have provided evidence that EFAs and their longer chain derivatives have a structural role in cell 
membranes, a role in the transport of other lipids and both direct and indirect roles in the activity 
of enzyme systems (7).   
The long-chain fatty acids have also been found to play a role in regulation of gene 
expression.  These LCPUFA enhance the DNA binding affinity of peroxisome proliferator-
activated receptors (PPARs), which regulate the genes involved in fatty acid and glucose 
oxidation, fatty acid uptake, fatty acid activation, triacylglycerol biosynthesis, and lipoprotein 
metabolism.  There is also some evidence that EPA enhances the transcriptional activity of this 
family of transcription factors; however, these findings need to be substantiated by live animal 
studies.  Synthesis and activation of the sterol regulatory element binding protein (SREBP)-1 is 
also influenced by unsaturated fatty acids.  The SREBP transcription factors regulate 
transcription of several of the genes involved in lipid, cholesterol, bile, and lipoprotein 
biosynthesis.  There is evidence that dietary ω3 fatty acids suppress hepatic lipogenesis by 
inhibition of SREBP-1 gene transcription and by increasing SREBP-1 mRNA decay (9).  The 
activity and abundance of hepatic nuclear factor 4α (HNF4α), a steroid receptor that enhances 
expression of genes involved in hepatic lipogenesis and carbohydrate metabolism, is modulated 
by the ω3 class of fatty acids.  Taken together, the genomic effects of ω3 fatty acids on hepatic 
metabolism involve a shift from triacylglycerol synthesis, storage, and apolipoprotein secretion 
towards hepatic oxidation of lipids.  This shift may influence the risk of developing several 
chronic diseases including coronary heart disease and obesity.   
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ARA and DHA make up the majority of the lipid content of the nervous system (10, 11).  
Fetal brain accumulation of LCPUFA rapidly increases during the third trimester of gestation 
and continues into the first two years after birth.  These LCPUFA are incorporated into highly 
specialized membrane phospholipids found in the retina and synapses.  ARA is found in 
relatively large amounts in most tissues, while DHA is distributed preferentially to specific 
tissues.  Compared to ARA, DHA is found in higher amounts in the cerebral cortex, retina and 
testis (12).  Within each of these tissues, DHA is especially abundant in rod photoreceptors and 
synaptic membranes.  These findings suggest an important role for the LCPUFA in visual and 
cognitive development.               
There is ample evidence that these LCPUFA are important for normal brain development, 
visual acuity and cognitive function.  Studies show that deficiency of the LCPUFAs is related to 
degenerative diseases of the retina (13-15), poor performance on a test of retinal function and 
tests of learning capabilities (10), memory loss, and diminished cognitive function (16). Infant 
supplementation studies point to relationships between LCPUFAs and better visual acuity (17-
25), and mental development (21, 25-29).   
Importance of LCPUFAs during Pregnancy 
Substrate transfer from the mother to the fetus is critical for successful conception and 
proper fetal growth.  The accretion of LCPUFA is especially important during the prenatal 
period for both the mother and the growing fetus.  There is a growing body of evidence that these 
nutrients are necessary for a variety of processes during gestation.  For the mother, these 
nutrients have been shown to play a role in the proper development of the placenta, in the 
initiation of labor and delivery, and possibly development of the mammary gland (30).  Studies 
of increased dietary LCPUFA and supplementation have shown positive effects in the prevention 
of pregnancy-induced hypertension and prolonging gestation in those women at risk of 
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delivering preterm (31).  Recent work found that low maternal plasma ω3 fatty acids and high 
ARA during early pregnancy were associated with a 40-50% increase in risk of small for 
gestational age (SFA) infants (32).  For the fetus these nutrients are important for proper growth 
(33, 34), are significantly related to anthropometric measurements at birth (35) and also 
influence neurological conditions at birth (36).  There is also a large pool of evidence that 
suggests the LCPUFA are especially important for postnatal growth and development of preterm 
infants (35, 37).     
Placental Transfer of ω3 and ω6 Fatty Acids 
The elongation and desaturation enzymes necessary for EFA conversion to DHA and 
ARA are present in the fetal liver during the early stages of gestation; however, their activity is 
very low before birth (38).  For this reason, the ω3 and ω6 LCPUFA that the fetus accumulates 
come from placental transfer from the mother.  To meet the additional needs of the growing 
fetus, the maternal diet should contain sufficient EFAs and their long chain derivatives.  If intake 
is too low to meet the physiological needs, maternal body stores may be mobilized to supply the 
required fatty acids (39).  These stores are usually made available during the third trimester of 
pregnancy when fetal growth reaches its maximum rate and fetal requirements for fatty acids, 
especially DHA and ARA, are greatly increased (40).  Evidence suggests that the accumulation 
of brain DHA and ARA is far more efficient from preformed, dietary DHA and ARA rather than 
their EFA precursors, LA and ALA.  Additionally, recent evidence points to an inefficiency in 
the conversion of DHA from ALA.  This raises the question of whether DHA may be considered 
conditionally essential during pregnancy when the requirement is increased. 
Extensive research has investigated the amount of LCPUFA that is transferred to the 
fetus in relation to the amount available in maternal circulation.  Results of these studies show 
that the amounts in cord blood (plasma phospholipids) are strongly correlated with maternal 
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plasma phospholipids (41, 42) and are influenced by the maternal diet (43).  This evidence 
supports previous findings of Otto et al. who showed that in an international population, the ω3 
LCPUFA concentrations in umbilical plasma, vein, and artery phsospholipids were the highest in 
those countries that had the highest maternal plasma ω3 LCPUFA concentrations (44).  In the 
same international population, ω6 LCPUFA concentrations in umbilical material seemed less 
dependent on the maternal ω6 LCPUFA concentrations in blood phospholipids, which 
researchers suggested could be due to some type of fetal autonomy with respect to establishing 
its ARA supply (44). 
In the very early stages of pregnancy, maternal plasma and erythrocyte DHA 
concentrations begin to increase without any concomitant change in dietary intake.  The increase 
is most probably due to the release of fatty acids from the maternal stores to provide the 
requirements for highly proliferating and differentiating tissues during this stage (45).   
Compounding the issue of insufficient maternal dietary DHA are the findings by Al et al 
(41).  In a prospective, longitudinal study the total concentration (mg/L) of fatty acids in 
maternal plasma phospholipids increased by ~51% throughout the course of pregnancy.  The 
absolute amount of ARA increased by 23% while DHA increased by 52%.  It was thought that 
the significant increase in DHA was due to an increase in fish intake; however, the dietary 
information for this population showed no increase in fat intake during pregnancy.       
Taken together, the body of evidence regarding DHA points to reduced maternal status 
during pregnancy with suboptimal supply for the fetus (46).  For this reason, the LCPUFA are 
often thought of as conditionally essential during pregnancy.  Further, the reduction in maternal 
EFA status over the course of pregnancy appears to be independent of cultural differences in 
dietary intake and ethnic origin (44).     
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The concentrations of DHA and ARA in fetal plasma phospholipids are much higher 
compared to the concentration in maternal phospholipids; however, the LA and ALA precursors 
are lower.  Research supports the notion that higher LCPUFA concentrations in fetal plasma 
reflect selective placental transfer, synthesis in placental or fetal tissues, or selective fetal 
retention.  Most evidence points to the selective transfer of ARA and DHA by membrane 
associated proteins with higher affinity and binding capacity for these LCPUFA than for other 
fatty acids.  Findings by Ghebremeskel et al. (2000) suggest the possible role of a physiological 
mechanism that works to maintain an appropriate balance between ARA and DHA (47).  
Early research suggested the existence of a mechanism within the placenta that allowed 
for fetal uptake of ARA by selective incorporation of ARA into phosphoglycerides and export to 
the fetal circulation (48).  These findings were followed by the purification and characterization 
of a fatty acid-binding protein (FABP) from human placentas (49).  This protein was isolated 
from aborted and term placentas and was found to have at least three distinct fractions: one that 
is nearly lipid-free, one that binds LCPUFA nonspecifically and one that binds mainly ARA.  
Further studies suggested a saturability of fatty acid binding and the occurrence of binding sites 
specific to different fatty acids (50).  Later research revealed that the FABP is located 
exclusively in the maternal facing microvillous membranes which may result in the 
unidirectional flow of maternal free fatty acids to the fetus (51).   
It was recently established that placental FABP preferentially binds both ARA and DHA 
(52).  These findings are further supported by the work of Haggerty (1997) and Dutta-Roy 
(2000) (53, 54).  Most recently, the involvement of two fatty acid transport proteins has been 
suggested to play a role in the placental transfer of LCPUFA.  The supply of DHA during 
pregnancy affects the expression of fatty acid transport proteins in the placenta and therefore 
plays a role in placental transfer (55, 56).  Taken together, these findings clearly indicate that the 
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fetus is dependent upon the maternal supply of substrates and also on adequate placental 
transport.   
Obesity, BMI, and Insulin Resistance 
Obesity is a condition marked by excess body fat.  Measures of height and body weight 
are widely used to identify the overweight and obese because it is difficult to obtain accurate 
measures of body fatness in populations.  Body Mass Index (BMI) is a measure used to assess 
body weight relative to height.  The number, obtained by dividing weight in kilograms (kg) by 
height in meters squared (m
2
), has a relatively high correlation with estimates of body fatness.  
As BMI increases above 25 kg/m
2
, there is a concomitant, gradual increase in risk of morbidity 
from conditions such as type 2 diabetes mellitus, hypertension, coronary heart disease, stroke, 
gallbladder disease, osteoarthritis, sleep apnea and some forms of cancer (prostate, colon, 
endometrial and breast).  See Table 1 for classification of BMI.    
Table 1. Classification of Overweight 




Underweight < 18.5 
Normal 18.5-24.9 
Overweight 25.0-29.9 
Obese ≥ 30.0 




Obesity and Pregnancy 
Current estimates, based on data from the Pregnancy Risk Assessment Monitoring 
System, show a 69% increase in pre-pregnancy obesity between 1993 and 2003 (57).  These data 
are supported by the finding that nearly 30% of women of childbearing age (20-39 years) were 
obese between 1999 and 2002.  The highest prevalence of obesity occurred in non-Hispanic 
black women (49%) followed by Mexican-Americans (38.9%) and non-Hispanic white women 
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(31.3%) (58).  Pre-pregnancy BMI is an important measure that is used by the Institute of 
Medicine to make weight gain recommendations for pregnancy (59).  Excess weight during 
pregnancy poses a risk for both the mother and the developing fetus.  Several adverse pregnancy 
outcomes including miscarriage, neural tube defects, preeclampsia, GDM, macrosomia, shoulder 
dystocia, and fetal death have been linked to high maternal BMI.        
Influence of BMI and Insulin Resistance on LCPUFA Transfer  
 Little is known about the maternal factors that may influence supply and transfer of 
substrates to the fetus during gestation.  There is evidence of altered lipid metabolism in 
pregnancies complicated by type 2 diabetes mellitus (NIDDM) and GDM (60).  In the animal 
model, increasing maternal glycemia has been associated with a decrease in the unidirectional 
transfer of both EFA and non-essential fatty acids.  Holman et al (1983) found that maternal 
diabetes was associated with an overall decrease in PUFA status in the whole animal (61).   
Decreased insulin sensitivity, seen in conditions of diabetes and obesity, has been associated 
with decreased concentration of PUFA in skeletal muscle and plasma phospholipids (62), (63).  
While little is known about the underlying mechanisms of these phenomena, it is suggested that 
there is a possible impairment in the enzymes that regulate EFA metabolism (64).  In a study of 
Pima Indians, a negative correlation was reported between high percentage of body fat and 
impaired activity of an enzyme involved in the EFA to LCPUFA conversion pathway.  Both 
pregnancy and obesity are often accompanied by decreased insulin sensitivity.  Any impairment 
in the enzyme system that results in decreased ARA or DHA would mean a smaller pool of these 
essential nutrients available for transfer to the fetus and, thus, could have severe, deleterious 
effects on fetal growth.  Increased insulin resistance is a phenomenon associated with normal 
pregnancies and to a greater extent in those complicated by diabetes (65).  
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 Abnormalities in placental transfer may also be a consequence of pregnancies 
complicated by insulin resistance and obesity.  Bitsanis et al (2006) found that women diagnosed 
with GDM had higher placental concentrations of both ARA and DHA when compared to 
control women (66).  These results could not be explained by differences in ethnicity or 
enhanced placental synthesis of the LCPUFAs.  Because neonates born to women with GDM 
tend to have low blood levels of AA and DHA, the authors hypothesize that GDM enhances 
uptake of the two fatty acids from maternal circulation and causes them to be retained instead of 
transferred to the fetus.  These results are supported by the findings of increased placental 
incorporation of ARA in pregnancies complicated by type 1 diabetes mellitus (IDDM) (67) and 
enhanced expression of placental FABP in pregnancies complicated by GDM (68).   
In a cohort of pregnant women, BMI appears to be a significant predictor of maternal 
concentrations of plasma phospholipid ARA and DHA (69), as well as fetal erythrocyte 
phospholipid DHA (70).  More recently, both IDDM and NIDDM have been shown to 
compromise maternal red blood cell (RBC) DHA, as well as cord plasma and RBC ARA and 
DHA (71).  These effects seem to be independent of ethnicity or diet and related more to the 











Participants and Sampling 
Sera from pregnant women living in Maine were collected in the decade between 1996 
and 2006.  The fatty acids of sera from 265 women who delivered term infants who were 
appropriate for gestational age were analyzed.  The sample population was selected from a larger 
population of 400 women who participated in a similar study.  Samples were collected during the 
second trimester of pregnancy from non-fasting women and stored in blood banks at FBR in 
Maine.  The 265 samples were shipped from FBR and upon arrival at the Louisiana State 
University nutrition lab were immediately placed in storage at -80
o
C.  Data for participants’ ages 
and BMIs, which were calculated at 13-18 weeks gestation, were also provided by FBR.  
Assessment of samples that had been in storage for five to ten years provided assurance that fatty 
acids were detectable and quantifiable.     
Procedures 
Sample Collection 
 Samples were shipped from FBR to the Knapp Hall laboratory overnight on dry ice.  
When samples arrived they were immediately transferred to a freezer and stored at -80
o
C until 
analysis for fatty acids began.   
Sample Methylation 
Sera fatty acids were methylated according to Lepage (73) using an internal standard.  In 
brief, 100 µl of the stored sera were transferred to 9 ml glass tubes with Teflon lined caps.  Two 
ml of methanol:benzene (4:1, v/v) containing 40 µg/ml of internal standard (heptadecanoic acid, 
C17:0) was added to the sample.  Working under a ventilated hood, 200 µl of acetyl chloride was 
added slowly over a period of one minute.  After the addition of acetyl chloride, samples were 
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capped tightly and mixed thoroughly.  Samples were heated for one hour at 100
 o
C in an analog 
heat block (VWR).  After one hour the samples were removed from the heat block and allowed 
to cool.  When samples were cool to the touch, 5 ml of 6% (w/v) potassium carbonate (K2CO3) 
was added to neutralize the mixture and stop the reaction.  Samples were then centrifuged in a 
Beckman refrigerated centrifuge for 10 minutes at ~3500 rpm.  After centrifuging, the methyl 
esters in the solvent were pipetted off as the top layer and placed in a glass vial labeled with the 
sample number.  Fatty acids were separated by gas chromatography, identified based on 
retention times and quantified against the internal standard.  Fatty acids were expressed as 
relative weight percent (wt%).     
Sample Analysis 
Analysis was performed using a Hewlett Packard 5890 series gas chromatograph (GC) 
equipped with flame ionization detection (FID).  Samples were injected into a 30 m fused silica 
column with an internal diameter of 0.32 mm (Omegawax 320).  The initial oven temperature 
was programmed at 190
o
C and increased to 210
o
C in increments of 2
o
/minute with a final hold of 
20 minutes.  Helium was used as the carrier gas with a flow set at 1.0 ml/minute and hydrogen 
was used as the make-up gas.  The split ratio was set at 1:50, which means one part in fifty 





respectively.  Each sample was injected into the chromatograph three times.  Peak identification 
of serum fatty acids was based on comparison with the relative retention times of single fatty 
acid methyl esters (FAME).  Relative weight percents were calculated using the following 
formula: 






The data set was analyzed using JMP® 8 from Statistical Analysis Software (SAS).  
Differences in relative weight percents of individual fatty acids and the ratios of fatty acids were 
determined using one-way analysis of variance (ANOVA).  Tukey’s Post-Hoc analyses were 
























RELATIONSHIP OF MATERNAL SERUM FATTY ACIDS AND BODY MASS INDEX 
Introduction 
 The polyunsaturated fatty acids docosahexaenoic acid (DHA, C22:6ω3) and arachidonic 
acid (ARA, C20:4ω6) are important components of the nervous system and have critical roles in 
fetal growth and in brain and retinal development and function.  Exponential fetal accretion of 
these fatty acids begins during the third trimester of gestation and continues into the first two 
years after birth.  Fetal conversion of the ω3 and ω6 fatty acids is low; therefore, fetal 
accumulation depends on the maternal supply.  The placenta plays an important role in 
transferring these fatty acids from maternal diet or body stores to the growing fetus.  Because the 
fetus depends on the maternal supply, the importance of identifying factors that influence fatty 
acid transfer is underscored.   
 During pregnancy there is a natural decrease in maternal LCPUFA status, in particular, 
DHA.  A suboptimal supply of EFAs as well as their long chain derivates could be detrimental to 
the development of the fetus.  In addition to this, some maternal conditions may impact placental 
transfer of nutrients to the fetus.  One such condition is insulin resistance that is seen in diabetes 
mellitus.  Several studies support an overall decrease in EFA and LCPUFA status in these 
conditions (60-65, 69, 70, 74).   
During pregnancy it is normal to experience some insulin resistance and this resistance is 
exacerbated by excess weight.  Data document that the number of women entering pregnancy as 
overweight or obese is increasing.  Together, these conditions, insulin resistance and excess 
weight, may negatively influence the efficiency of nutrient transfer.  Recently, maternal BMI has 
been shown to be negatively related to plasma phospholipid concentrations of ARA and DHA 
(69) as well as fetal erythrocyte phospholipid DHA (70).  The objective of the current study was 
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to determine if there is a similar relationship between maternal serum fatty acids and BMI.  If 
these results mimic the results of studies of phospholipid fatty acids, more studies using total 
lipids in stored sera may be feasible as a more convenient and relatively rapid way to investigate 
the maternal factors that influence substrate transfer to the fetus as well as fetal outcomes.       
Subjects and Methods 
Subjects 
Sera from pregnant women living in Maine were collected in the decade between 1996 
and 2006.  Samples were collected during the second trimester of pregnancy from non-fasting 
women.  These samples were shipped from the Foundation for Blood Research in Maine and 
upon arrival at the Louisiana State University nutrition lab were immediately placed in storage at 
-80
o
C.  Data for women’s ages and BMIs, which were determined at approximately 13-18 weeks 
gestation, were provided by FBR.  Prior assessment of samples that had been in storage for five 
to ten years provided assurance that length of storage would not be a significant factor.  The fatty 
acids in sera from 265 women who delivered term infants who were appropriate for gestational 
age were analyzed for this study. 
Sample Analysis 
Samples were directly methylated following the LePage method (73).  In brief, 100 µl of 
the stored sera were transferred to 9 ml glass tubes with Teflon lined caps.  Two ml of 
methanol:benzene (4:1, v/v) containing 40 µg/ml of internal standard (heptadecanoic acid, 
C17:0) was added to each tube.  Working under a ventilated hood, 200 µl of acetyl chloride was 
added slowly over a period of one minute.  After the addition of acetyl chloride, samples were 
capped tightly and mixed thoroughly.  Samples were heated for one hour at 100
 o
C in an analog 
heat block (VWR).  After one hour the samples were removed from the heat block and allowed 
to cool.  Once cooled, 5 ml of 6% (w/v) potassium carbonate (K2CO3) was added to neutralize 
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the mixture and stop the reaction.  Samples were centrifuged in a Beckman refrigerated 
centrifuge for 10 minutes at ~3500 rpm.  After centrifuging, the methyl esters in the solvent were 
pipetted off as the top layer and placed in a glass vial labeled with the sample number.  
Fatty acid analysis was performed using a Hewlett Packard 5890 series gas 
chromatograph equipped with flame ionization detection.  Samples were injected into a 30 m 
fused silica column with an internal diameter of 0.32 mm (Omegawax 320).  The initial oven 
temperature was programmed at 190
o
C and increased to 210
o
C in increments of 2
o
/minute with a 
final hold of 20 minutes.  Helium was used as the carrier gas with a flow set at 1.0 ml/minute and 
hydrogen was used as the make-up gas.  The split ratio was set at 1:50.  The injection port and 




C, respectively.  Each sample was injected into 
the chromatograph three times.  Peak identification of serum fatty acids was based on 
comparison with the relative retention times of single fatty acid methyl esters (FAME).  Relative 
weight percents were calculated using the following formula: 
      (area % of single FAME * 100)/(total area % of fatty acids – area % of C17:0) 
Statistical Analysis 
The data were analyzed using JMP® 8 from Statistical Analysis Software (SAS).  
Differences between BMI categories in relative weight percents of individual fatty acids and the 
ratios of fatty acids were determined using one-way analysis of variance (ANOVA).  Tukey’s 
Post-Hoc analyses were performed to determine where significant differences occurred between 
BMI groups.     
Results 
Sample Characteristics 
 The 265 participants had an average age of 27.7 years and an average BMI of 27.5 kg/m
2
.  
Participants were grouped according to BMI category (Table 2; < 18.5, underweight; 18.5-24.9, 
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normal; 25.0-29.9, overweight; ≥ 30.0, obese).  For statistical analysis, participants under age 18 
were excluded as well as six participants in the obese class III category with outlying BMIs and 
two participants with outlying weight percents for several fatty acids.   
Table 2. Characteristics of sample population
 
BMI Category Samples (n) % of Population 
Normal weight 110 44.2 
Overweight 74 29.7 
Obese 65 26.1 
 
Serum Fatty Acid Analysis 
Saturated, ω3, and ω6 fatty acids are presented in Tables 3, 4, and 5, respectively.  There 
were significant differences for the saturated fatty acid lignoceric acid (C24:0) in normal versus 
obese participants (Table 3, p = 0.03).  Weight percent of the ω3 fatty acid eicosapentanoic acid 
(EPA, C20:5n3) was significantly different between the overweight and obese participants 
(Table 4, p = 0.02) while the total relative weight percent of DHA trended toward significant 
difference (p=.08) (Table 4).  In the overall model there was a significant difference for the total 
ω3 LCPUFA (p =.04); however, Tukey’s Post-Hoc analysis failed to determine significant 
differences between BMI categories.  In general, participants with higher BMIs tended to have 
lower total ω3 LCPUFA (∑ C20:5ω3 and C22:6ω3).      
Table 3. Average relative weight percent (wt %) of saturated fatty acids by BMI category
1 
 Normal Overweight Obese 
C16:0 27.37 ± 0.32 [110] 28.13 ± 0.39 [74] 28.33 ± 0.42 [65] 
C18:0 5.52 ± 0.13 [110] 5.42 ± 0.17 [72] 5.42 ± 0.17 [65] 
C20:0 2.06 ± 0.14 [109] 1.98 ± 0.17 [73] 2.01 ± 0.18 [63] 
C22:0 1.27 ± 0.05 [106] 1.18 ± 0.06 [71] 1.19 ± 0.07 [62] 
C24:0
 
0.95 ± 0.06 [110]
a 
1.09 ± 0.07 [74]
a 





Mean ± standard error.  Means within a row with different superscript letters indicate 










Table 4. Average relative weight percent (wt %) for the ω3 fatty acids by BMI category
1 
 Normal Overweight Obese 
C18:3ω3 1.70 ± 0.16 [100] 1.75 ± 0.20 [67] 1.99 ± 0.21 [62] 
C20:5ω3 1.38 ± 0.04 [110]
a 
1.27 ± 0.05 [74]
a 
1.17 ± 0.06 [65]
b 
C22:6ω3 1.59 ± 0.04 [110] 1.73 ±0.05 [74] 1.57 ± 0.06 [65] 
1
Mean ± standard error.  Means within a row with different superscript letters indicate 
significant differences among BMI categories, p ≤ 0.05.  Sample number in brackets.   
Table 5. Average relative weight percent (wt %) for the ω6 fatty acids by BMI category
1 
 Normal Overweight Obese 
C18:2ω6 24.07 ± 0.37 [110] 23.71 ± 0.45 [74] 23.42 ± 0.48 [65] 
C18:3ω6 1.59 ± 0.19 [26] 1.25 ± 0.22 [19] 1.37 ± 0.28 [12] 
C20:2ω6 1.14 ± 0.14 [100] 0.84 ± 0.16 [72] 0.89 ± 0.17 [65] 
C20:3ω6 1.32 ± 0.06 [110] 1.37 ± 0.07 [74] 1.29 ± 0.08 [64] 
C20:4ω6 2.88 ± 0.09 [110] 2.99 ± 0.11 [74] 2.96 ± 0.12 [65] 
C22:2ω6
 
0.53 ± 0.09 [10] 0.59 ± 0.11 [6] 0.38 ± 0.20 [2] 
 
1
Mean ± standard error.  Sample number in brackets.  
  
Table 6. Sums and ratios of serum fatty acid content (wt %)
1 
 Normal Overweight Obese 
Total ω3 PUFA 4.48 ± 0.16 [110] 4.53 ± 0.19 [74] 4.58 ± 0.20 [65] 
Total ω6 PUFA 29.73 ± 0.37 [110] 29.26 ± 0.45 [74] 28.81 ± 0.48 [65] 
SFA:ω3 PUFA 9.22 ± 0.30 [110] 9.18 ± 0.36 [74] 9.30 ± 0.38 [65] 
SFA:ω6 PUFA 1.27 ± 0.02 [110] 1.32 ± 0.03 [74] 1.33 ± 0.03 [65] 
ω3:ω6 0.15 ± 0.01 [110] 0.16 ± 0.01 [74] 0.16 ± 0.01 [65] 
Total ω3 LCPUFA
 
2.97 ± 0.06 [110] 3.00 ± 0.08 [74] 2.74 ± 0.08 [65] 
Total ω6 LCPUFA 5.28 ± 0.22 [110] 5.23 ± 0.27 [74] 5.14 ± 0.29 [65] 
ω3 LCPUFA:ω6 LCPUFA 0.65 ± 0.02 [110] 0.64 ± 0.03 [74] 0.58 ± 0.03 [65] 
DHA:ARA 0.60 ± 0.02 [110] 0.63 ± 0.03 [74] 0.56 ± 0.03 [65] 
Total SFA 37.14 ± 0.33 [110] 37.59 ± 0.41 [74] 37.64 ± 0.43 [65] 
Total PUFA 34.19 ± 0.42 [110] 33.76 ± 0.51 [74] 33.38 ± 0.54 [65] 




Mean ± standard error.  PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; 
LCPUFA, long-chain polyunsaturated fatty acid; DHA, docosahexaenoic acid; ARA, 




In this study we have established that sera collected from pregnant women and stored for 
a decade or so may be used to study relationships of fatty acid status, maternal risk factors, and 
pregnancy outcomes.  In previous research, positive relationships were found between higher 
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BMI and lower ω3 fatty acid concentrations in plasma phospholipids (69, 70).  Similar results for 
total serum lipids were found in this study with participants in the highest BMI category tending 
to have lower total ω3 LCPUFA, and statistically, significantly lower EPA.   
The findings of this study support the theory that BMI is a predictor of maternal 
LCPUFA status and suggest that stored serum may be a feasible medium to further explore the 
relationships between maternal factors that influence pregnancy and fetal outcomes.  These 
results are limited by the lack of dietary intake information in this group as well as the absence of 
pre-pregnancy BMI.  The nature of the sample is also a limitation because of the influence of 
recent dietary intake.  The serum contains fatty acids bound to triglycerides, which would reflect 
recent intake, as well as fatty acids contained in phospholipid membranes.   
In this study, phospholipids were not extracted from the sera.  The samples were analyzed 
for total fatty acid content as a convenient and relatively quick way of investigating the 
relationship between maternal BMI and fatty acid content of sera.  It is interesting to note that a 
similar relationship was found using the srea as was found in previous studies using plasma 
phospholipids.  This suggests the plausibility of analyzing serum in this population to investigate 
maternal factors influencing LCPUFA status.  Sera is often stored after routine blood collections 
and archived over many years and demographic areas.  Using stored sera to explore fatty acid 
status during pregnancy provides a unique opportunity to find relationships in a large number of 
samples that include many different populations.  In addition to the availability of a large number 
of samples, the methodology for total serum fatty acid analysis is less laborious than the 
methodology for plasma phospholipids.  To further investigate these relationships, future studies 
should include a more diverse sample population and control for dietary intake, supplementation, 






The purpose of the present study was to investigate the relationship between maternal 
serum fatty acids and BMI.  The fatty acid content of serum was analyzed in 265 women in their 
second trimester of pregnancy.  Serum samples were provided by the Foundation for Blood 
Research in Maine along with maternal age and BMI.  Sera were collected between 1996 and 
2006 and maternal BMIs were calculated at 13-18 weeks gestation.  These samples provided a 
unique opportunity to examine a relationship that has previously been reported in studies of 
plasma phospholipids.  Participants were grouped by BMI category and after analysis using gas 
chromatography, fatty acid concentrations were compared across BMI categories.   
 In the sample population, women with the highest BMIs tended to have lower total 
weight percent of the ω3 LCPUFA DHA and statistically, significantly lower EPA.  These 
findings are in line with recent reports that maternal BMI negatively influences plasma 
phospholipid concentrations of DHA and ARA in the third trimester of pregnancy (69).   
DHA is especially important for fetal growth and development.  During the last trimester 
of pregnancy, brain accumulation rapidly increases and continues until the age of two.  Maternal 
supply of preformed LCPUFA is critical for the growing fetus.  Activity of the elongation and 
desaturation enzymes needed for production of LCPUFAs from EFAs is low in the fetus; 
therefore, the ω3 and ω6 LCPUFAs that the fetus accumulates must be transferred from the 
mother across the placenta.  Maternal dietary intake and body stores provide sources of the 
LCPUFAs.  Because tissue accumulation of the fatty acids is more efficient from preformed 
DHA and ARA than from their 18-carbon parent fatty acids, it is important that the mother 
provide sufficient amounts of these LCPUFAs.  There is strong evidence that the amount of 
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LCPUFAs transferred to the fetus is strongly related to maternal plasma phospholipid 
concentrations and dietary intake (41-44).   
Because the fetus relies on maternal supply of LCPUFA, there are many maternal factors 
that may negatively impact the amount that is transferred.  Animal studies investigating the 
influence of maternal insulin resistance on substrate transfer found an overall decrease in PUFA 
status in the presence of diabetes (61).  In human models, decreased insulin sensitivity has been 
associated with decreased PUFA concentrations in skeletal muscle (62) and plasma 
phospholipids (63).  Insulin resistance is often seen in conditions of diabetes and obesity and it is 
normal to see decreased insulin sensitivity during pregnancy.  There is great concern considering 
the 69% increase in prepregnancy obesity reported between 1993 and 2003 (57).  If maternal  
LCPUFA supply is inadequate, the consequences could be deleterious since these nutrients are 
important for proper fetal growth (34, 75) and are significantly related to anthropometric 
measures (35) and neurological conditions (36) at birth.     
This study lends support to findings that BMI is a predictor of maternal ω3 LCPUFA 
concentrations.  However, these data are limited by several factors.  Serum is not the preferred 
sample for assessing fatty acid status as it is a reflection of both dietary intake and fatty acids of 
cell membranes rather than fatty acids of the membrane phospholipids that are known to reflect 
fatty acids of tissues cells, i.e. fatty acid status (76).  In addition, ideally, blood should have been 
drawn after a fast.  Also, the maternal BMIs provided were calculated well into pregnancy at 
approximately 13-18 weeks gestation.  This BMI is likely to represent baseline BMI plus the 
amount of weight the mother gained up to that point in pregnancy.  Perhaps a more accurate BMI 
would have been calculated before pregnancy, which would represent baseline BMI.  Finally, 
these results are only applicable to women of similar age, race, parity, and health status.  Based 
on these findings we conclude that women with increased BMI may be at risk for inadequate 
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PUFA supply to the fetus.  More studies are needed to determine the impact of maternal BMI 
and insulin resistance on placental transfer of LCPUFAs as well as the physiologic mechanisms 
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